Trial reportCardiovascular diabetology2003
Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.
Trial report in Cardiovascular diabetology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 5 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- Effects of trimetazidine on cardiac function and ventricular remodeling in patients with ischemic cardiomyopathy: a systematic review and meta-analysis.General thoracic and cardiovascular surgery · 2025Pooled it
- Optimal effectiveness of heart failure management - an umbrella review of meta-analyses examining the effectiveness of interventions to reduce (re)hospitalizations in heart failure.Heart failure reviews · 2022Pooled it
- Meta-analysis of trimetazidine treatment for cardiomyopathy.Bioscience reports · 2018Pooled it
- Pooled it
- Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials.Clinical cardiology · 2011Pooled it
- Effect of trimetazidine on left ventricular functions and cardiac biomarkers in diabetic patients with left ventricular diastolic dysfunction: a randomized controlled trial.Scientific reports · 2025Trial
- Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial.ESC heart failure · 2023Trial
- Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy.Heart (British Cardiac Society) · 2005Trial
- Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy - Six months follow-up result.Indian heart journalTrial
- Trimetazidine in Chronic Coronary Syndrome and Coronary Artery Disease: A Narrative Review of Clinical Efficacy, Safety, and Current Guideline Position.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Metabolic Adaptation of CD8⁺ T Cells Limits the Efficacy of Fatty Acid Oxidation Inhibition in Type 1 Diabetes.International journal of biological sciences · 2026Article
- Recent advances associated with cardiometabolic remodeling in diabetes-induced heart failure.American journal of physiology. Heart and circulatory physiology · 2024Review
- Neuroprotective Effects of Trimetazidine against Cisplatin-Induced Peripheral Neuropathy: Involvement of AMPK-Mediated PI3K/mTOR, Nrf2, and NF-Oxidative medicine and cellular longevity · 2024Article
- Trimetazidine Reduces Cardiac Fibrosis in Rats by Inhibiting NOX2-Mediated Endothelial-to-Mesenchymal Transition.Drug design, development and therapy · 2022Article
- Mitochondrial Mechanisms in Diabetic Cardiomyopathy.Diabetes & metabolism journal · 2020Review
- Trimetazidine in Heart Failure.Frontiers in pharmacology · 2020Review
- The Effects of Trimetazidine on QT-interval Prolongation and Cardiac Hypertrophy in Diabetic Rats.Arquivos brasileiros de cardiologia · 2019Article
- Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles.Nature reviews. Cardiology · 2019Review
- Trimetazidine and Other Metabolic Modifiers.European cardiology · 2018Review
- Metabolic Modulation of Cardiac Metabolism in Heart Failure.Cardiac failure review · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with diabetic cardiomyopathy have an impaired myocardial glucose handling and distal distribution of coronary atherosclerosis. Trimetazidine, an anti-ischemic metabolic agent, improves myocardial glucose utilization though inhibition of fatty acid oxidation. Aim of the present study was to evaluate whether the metabolic effect of trimetazidine on left ventricular function in patients with diabetic cardiomyopathy.
methods32 patients (24 males and 8 females, mean (SE) age = 67 +/- 6 years) with type 2 diabetes and ischemic cardiomyopathy were randomized to receive either trimetazidine (20 mg, t.d.s.) or placebo (t.d.s.) for six months in a randomized parallel study. Patients performed an echocardiogram at baseline and after 6 months.
resultsDemographic data were comparable between the two groups. After six month baseline left ventricular end-diastolic diameters increased from 62.4 +/- 1.7 to 63 +/- 2.1 mm in the placebo group, while decreased from 63.2 +/- 2.1 to 58 +/- 1.6 mm (p < 0.01 compared to baseline) in the trimetazidine group. Compared to baseline, left ventricular ejection fraction increased by 5.4 +/- 0.5% (p < 0.05) in the trimetazidine group while remained unchanged in the placebo group -2.4 +/- 1.1% (NS), p < 0.01 between groups. A significant improvement in wall motion score index and in the E/A wave ratio was detected in patients treated with trimetazidine, but not in those receiving placebo.
conclusionin diabetic patients with ischemic heart disease trimetazidine added to standard medical therapy has beneficial effect on left ventricular volumes and on left ventricular ejection fraction compared to placebo. This effect may be related to the effect of trimetazidine upon cardiac glucose utilization.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.